Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024

This report describes effectiveness of nirsevimab against respiratory syncytial virus-associated hospitalizations in infants.
Source: CDC Morbidity and Mortality Weekly Report - Category: American Health Tags: MMWR Morbidity & Mortality Weekly Report Respiratory Syncytial Virus Infection (RSV) Source Type: news